Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 19.69 is 41% above its 5-year average of 13.95, around the middle of its 5-year range (5.06–42.22).
As of the fiscal period ended Tuesday, June 30, 2026. 87.22% above its 12-month average of 10.52.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 19.69.
QUICK RATIO (ACID-TEST)
19.69
QUICK RATIO (ACID-TEST) AVG TTM
10.52
QUICK RATIO (ACID-TEST) AVG 3Y
9.84
QUICK RATIO (ACID-TEST) AVG 5Y
13.95
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+87.22%
CURRENT VS 3Y AVG
+100.04%
CURRENT VS 5Y AVG
+41.21%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
2.99
median of 649 covered companies
CURRENT VS SECTOR MEDIAN
+558.63%
vs the sector median at left
Faeth Therapeutics, Inc.
Market Cap
$718.65M
Quick Ratio (Acid-Test)
19.69
TTM Avg
10.52
3Y Avg
9.84
5Y Avg
13.95
Market Cap
$711.45M
Quick Ratio (Acid-Test)
8.86
TTM Avg
10.22
3Y Avg
11.35
5Y Avg
25.38
Market Cap
$717.44M
Quick Ratio (Acid-Test)
0.84
TTM Avg
1.18
3Y Avg
1.08
5Y Avg
1.08
Market Cap
$695.70M
Quick Ratio (Acid-Test)
14.20
TTM Avg
2.59
3Y Avg
2.42
5Y Avg
2.06
Market Cap
$731.71M
Quick Ratio (Acid-Test)
19.31
TTM Avg
14.05
3Y Avg
7.67
5Y Avg
5.91
Market Cap
$726.43M
Quick Ratio (Acid-Test)
3.86
TTM Avg
4.81
3Y Avg
5.95
5Y Avg
7.14
Market Cap
$735.04M
Quick Ratio (Acid-Test)
0.95
TTM Avg
4.92
3Y Avg
2.98
5Y Avg
5.72
Market Cap
$687.32M
Quick Ratio (Acid-Test)
5.53
TTM Avg
8.02
3Y Avg
10.47
5Y Avg
14.43
Market Cap
$674.55M
Quick Ratio (Acid-Test)
10.97
TTM Avg
8.63
3Y Avg
10.75
5Y Avg
10.66
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | $718.65M | 19.69 | 10.52 | 9.84 | 13.95 |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $711.45M | 8.86 | 10.22 | 11.35 | 25.38 |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $717.44M | 0.84 | 1.18 | 1.08 | 1.08 |
| Anteris Technologies Global Corp. (AVR)vs › | $695.70M | 14.20 | 2.59 | 2.42 | 2.06 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $731.71M | 19.31 | 14.05 | 7.67 | 5.91 |
| Cytek Biosciences, Inc. (CTKB)vs › | $726.43M | 3.86 | 4.81 | 5.95 | 7.14 |
| Achieve Life Sciences, Inc. (ACHV)vs › | $735.04M | 0.95 | 4.92 | 2.98 | 5.72 |
| Annexon, Inc. (ANNX)vs › | $687.32M | 5.53 | 8.02 | 10.47 | 14.43 |
| Helus Pharma Inc. (HELP)vs › | $674.55M | 10.97 | 8.63 | 10.75 | 10.66 |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $675.40M | 8.03 | 12.16 | 13.50 | 14.42 |
Quick Ratio
19.69
Excludes inventory
Current Ratio
19.69
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 19.69 |
| 2026-03-31 | 14.39 |
| 2025-12-31 | 5.06 |
| 2025-09-30 | 5.81 |
| 2025-06-30 | 7.64 |
| 2025-03-31 | 6.82 |
| 2024-12-31 | 7.70 |
| 2024-09-30 | 8.84 |
| 2024-06-30 | 10.90 |
| 2024-03-31 | 12.07 |
| 2023-12-31 | 11.92 |
| 2023-09-30 | 11.86 |
| 2023-06-30 | 15.13 |
| 2023-03-31 | 13.00 |
| 2022-12-31 | 11.98 |
| 2022-09-30 | 13.95 |
| 2022-06-30 | 23.46 |
| 2022-03-31 | 18.27 |
| 2021-12-31 | 30.38 |
| 2021-09-30 | 30.05 |
| 2021-06-30 | 42.22 |
| 2021-03-31 | 69.81 |
| 2020-12-31 | 4.16 |
| 2020-09-30 | 0.94 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 0.02 |
